Home Ingredients Sparassis crispa (Cauliflower Mushroom / Hanabiratake)
Immune SupportAnti-InflammatoryAntioxidant

Sparassis crispa (Cauliflower Mushroom / Hanabiratake)

Sparassis crispa — Sparassidaceae. Japanese name 'Hanabiratake'
Evidence Level
Limited
3 Clinical Trials
7 Documented Benefits
2/5 Evidence Score

Edible mushroom (Japanese name 'Hanabiratake') with the highest β-glucan content among medicinal mushrooms (>40% dry weight). Now cultivable in Japan on coniferous sawdust. The active polysaccharide SCG (Sparassis Crispa Glucan) is a unique 6-branched 1,3-β-glucan (one branch ~every 3 main-chain units) that activates innate immunity via Dectin-1. Most evidence is preclinical — Sarcoma 180 mouse antitumor model, cyclophosphamide-induced leukopenia recovery, anti-angiogenic and anti-metastatic effects. Human RCT data is limited.

Studied Dose β-glucan >40% of dry weight. Limited human RCT dosing data.
Active Compound Sparassis crispa β-glucan (SCG) — 6-branched 1,3-β-glucan; sparassol (antimicrobial); polyphenols.

Benefits

Highest β-glucan content (>40% dry weight)

Sparassis crispa contains over 40% β-glucan by dry weight — the highest content among medicinal mushrooms. The dominant active is SCG (Sparassis Crispa Glucan), a unique 6-branched 1,3-β-glucan with approximately one branch every 3 main-chain units. Distinguishing chemistry that supports the immune-activation mechanism rationale.

Supported by Trial 1, Trial 2

Antitumor activity in Sarcoma 180 mouse model

Polysaccharide fractions of SCG are characterized as 6-branched 1,3-β-glucans. All fractions showed antitumor activity in solid Sarcoma 180 mice, with strong vascular dilation and hemorrhage reactions. Tumor size dose-dependently decreased after 5 weeks of oral administration (10 or 100 mg/kg); survival was higher in treated animals. Preclinical mouse model — not translated to human cancer trials.

Supported by Trial 1

Hematopoietic recovery from chemotherapy

SCG enhanced the hematopoietic response in cyclophosphamide-induced leukopenic mice via either intraperitoneal or oral administration. Mechanistic basis for the integrative-oncology chemotherapy-support positioning. Animal evidence; human translation pending.

Supported by Trial 1, Trial 2

Dectin-1 / GM-CSF immunomodulation pathway

SCG induces GM-CSF production and upregulates Dectin-1 expression, leading to IFN-γ, TNF-α, and IL-12p70 induction. Blocking Dectin-1 significantly inhibited TNF-α and IL-12p70 induction — establishing Dectin-1 as the central receptor for SCG immunomodulation. Foundational mechanism evidence.

Supported by Trial 1, Trial 2

Anti-angiogenic and anti-metastatic effects

Anti-angiogenic and anti-metastatic effects of β-1,3-D-glucan from Hanabiratake have been reported, via a tumor neovascularization inhibition mechanism. Preclinical work supporting integrative-oncology research interest.

Supported by Trial 2

Sparassol — unique antimicrobial compound

Sparassol is a compound found in Sparassis crispa with antimicrobial activity. The unique-to-the-species small-molecule complement to the polysaccharide bioactivity, though clinical data on sparassol alone is sparse.

Supported by Trial 1, Trial 3

Limited human RCT data (honest assessment)

A systematic review and meta-analysis confirms that human RCT data on Sparassis crispa remains limited. Reviews confirm broad biological properties (anti-tumor, immune-enhancing, hematopoietic, anti-angiogenic, anti-inflammatory, anti-diabetic, wound-healing, antioxidant, anti-coagulant, anti-hypertensive) but most evidence is preclinical. A lower human-evidence position than Reishi, Chaga, or Turkey Tail despite the distinguishing chemistry.

Supported by Trial 3, Trial 2

Mechanism of action

1

6-branched 1,3-β-glucan (SCG) Dectin-1 binding

The SCG polysaccharide has a distinguishing 6-branched 1,3-β-glucan structure. Branched β-glucans bind Dectin-1 receptors on innate immune cells (macrophages, dendritic cells, neutrophils), triggering immune activation. The branching pattern is the structural basis for the mushroom's immune-activating profile.

2

GM-CSF induction → cytokine cascade

Dectin-1 binding induces GM-CSF production, which in turn drives a cytokine cascade including IFN-γ, TNF-α, and IL-12p70 — supporting Th1-skewed immune responses with anti-tumor and anti-pathogen relevance.

3

Hematopoietic response enhancement

SCG enhances bone marrow hematopoiesis post-chemotherapy in cyclophosphamide-induced leukopenia models. Mechanism for the chemotherapy-recovery positioning.

4

Anti-angiogenic and anti-metastatic effects

β-1,3-D-glucan inhibits tumor neovascularization in animal models. Preclinical mechanism relevant to integrative-oncology research, not yet translated to human trials.

5

Sparassol antimicrobial activity

Sparassol — a small-molecule compound unique to Sparassis crispa — shows antimicrobial activity against various pathogens. Mechanistic complement to the β-glucan immunomodulation.

6

Multi-mechanism reports (anti-inflammatory, antioxidant, anti-coagulant)

Reviews compiled reports of anti-inflammatory, antioxidant, anti-coagulant, and anti-hypertensive activity. The anti-coagulant activity warrants theoretical bleeding caution — a reasonable hypothesis-generating signal but not yet translated to human safety endpoints.

Clinical trials

1
SCG Sarcoma 180 Mouse Model (Ohno, Foundational)

Clinical evidence on Sparassis crispa (Cauliflower Mushroom / Hanabiratake) for the indications and outcomes described.

Clinical population described in trial publication.

Ohno N et al. Primary structures of SCHWE1v, SCCA, and SCHA polysaccharide fractions characterized as 6-branched 1,3-β-glucans. All fractions showed antitumor activity in solid Sarcoma 180 ICR mice with strong vascular dilation and hemorrhage reactions. Dose-dependent tumor reduction after 5 weeks oral administration (10 or 100 mg/kg); higher survival rates. Foundational structure-activity work — preclinical only.

2
Anti-Angiogenic + Anti-Metastatic β-1,3-D-Glucan

Clinical evidence on Sparassis crispa (Cauliflower Mushroom / Hanabiratake) for the indications and outcomes described.

Clinical population described in trial publication.

Yamamoto K et al. 2009 (Biol Pharm Bull 32:259-263, doi:10.1248/bpb.32.259). Anti-angiogenic and anti-metastatic effects of β-1,3-D-glucan from Hanabiratake. Preclinical mechanism work supporting integrative-oncology research interest.

3
S. crispa Evidence Review + Evidence Synthesis

Evidence review and pooled analysis of S. crispa clinical trials.

Clinical population described in trial publication.

Evidence review and pooled analysis of S. crispa clinical trials. Confirmed limited human clinical trial data. Positions Sparassis crispa as a preclinical-strong, human-evidence-emerging medicinal mushroom.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated; edible mushroom (now cultivable in Japan).
Mild GI upset (rare).
Pregnancy/lactation: limited specific data.
Long-term safety: limited human data — most evidence preclinical.
Allergic reactions in mushroom-sensitive individuals.
Anti-coagulant activity reported (Sharma 2022 review): theoretical bleeding risk.
Severely immunocompromised individuals: caution (immune activation potential).

Important Drug interactions

Chemotherapy: theoretically complementary per cyclophosphamide hematopoietic enhancement preclinical evidence — discuss with oncologist.
Anti-angiogenic medications: theoretical additive effect (mechanism overlap).
Anticoagulants: theoretical caution due to anti-coagulant activity reports.
Immunosuppressants: theoretical caution due to immune activation.
Most medications: no documented interactions.
Other mushroom supplements: compatible.

More Immune Support Ingredients

Immune Support
Vitamin C
Vitamin C (L-ascorbic acid) is a water-soluble essential nutrient that humans cannot synth…
Immune Support
Zinc
Zinc, an essential trace mineral, is commonly supplemented in forms like zinc gluconate, a…
Immune Support
Vitamin A
Vitamin A is a fat-soluble nutrient essential for vision, immune defense, reproduction, an…
Immune Support
EpiCor® (Postbiotic Yeast Fermentate — Cargill)
EpiCor is a postbiotic ingredient from Cargill, derived from the fermentation of Saccharom…

Frequently asked questions about Sparassis crispa (Cauliflower Mushroom / Hanabiratake)

What is Sparassis crispa used for?

Sparassis crispa (cauliflower mushroom) is a medicinal and edible mushroom notable for being exceptionally high in beta-glucans. It is studied for immune support, skin health, and healthy circulation and blood sugar.

Why is Sparassis crispa high in beta-glucans?

Cauliflower mushroom contains an unusually high proportion of beta-glucans (often cited around 40% of its dry weight), which is why it is of particular interest for immune and skin research among medicinal mushrooms.

How much Sparassis crispa should I take?

Doses depend on the extract; follow product labeling and look for standardized beta-glucan content. It can also be eaten as a food.

Is Sparassis crispa safe?

It is generally well tolerated as a food and supplement. As with other immune-active mushrooms, those on immune-modulating medication should check with a doctor.

What is Sparassis crispa?

Edible mushroom (Japanese name 'Hanabiratake') with the highest β-glucan content among medicinal mushrooms (>40% dry weight). Now cultivable in Japan on coniferous sawdust.

What is the recommended dosage of Sparassis crispa?

The clinically studied dose is β-glucan >40% of dry weight. Limited human RCT dosing data. Always follow the product label and check with a healthcare provider for personal advice.

Is Sparassis crispa safe, and does it have side effects?

For most healthy adults, Sparassis crispa is well tolerated at studied doses. Reported effects can include: Generally well-tolerated; edible mushroom (now cultivable in Japan). Mild GI upset (rare). It may also interact with some medications. Sparassis crispa is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Sparassis crispa interact with any medications?

Possible interactions include: Chemotherapy: theoretically complementary per cyclophosphamide hematopoietic enhancement preclinical evidence — discuss with oncologist. Anti-angiogenic medications: theoretical additive effect (mechanism overlap). If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Sparassis crispa?

NutraSmarts rates the evidence for Sparassis crispa as Limited (2 out of 5). It is backed by 3 clinical trials and 3 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(3 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Ohno N, Miura NN, Nakajima M, Yadomae T Antitumor 1,3-beta-glucan from cultured fruit body of Sparassis crispa Biol Pharm Bull. 2000;23(7):866-72. doi:10.1248/bpb.23.866.PubMedUsed to support: Animal study demonstrating antitumor activity of SCG (Sparassis crispa 1,3-β-glucan) against Sarcoma 180 solid tumors in ICR mice with marked vascular response; establishes antitumor activity and characterizes the active glucan fraction.
  2. Harada T, Miura NN, Adachi Y, Nakajima M, Yadomae T, Ohno N IFN-gamma induction by SCG, 1,3-beta-D-glucan from Sparassis crispa, in DBA/2 mice in vitro J Interferon Cytokine Res. 2002;22(12):1227-39. doi:10.1089/10799900260475759.PubMedUsed to support: In vitro mechanistic study showing SCG induces IFN-gamma production from murine splenocytes, establishing immunomodulatory (Dectin-1 / cytokine pathway) mechanism underlying SCG's anti-tumor and immune effects.
  3. Nameda S, Harada T, Miura NN, Adachi Y, Yadomae T, Nakajima M, Ohno N Enhanced cytokine synthesis of leukocytes by a beta-glucan preparation, SCG, extracted from a medicinal mushroom, Sparassis crispa Immunopharmacol Immunotoxicol. 2003;25(3):321-35. doi:10.1081/iph-120024500.PubMedUsed to support: In vitro study using human leukocytes showing SCG from S. crispa dose-dependently enhances cytokine production (including GM-CSF), confirming immunomodulatory activity in human cells; supports Dectin-1/GM-CSF pathway and hematopoietic recovery rationale.